Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose ruxolitinib vs MMF for GVHD prophylaxis in haploidentical HSCT with low-dose ATG
ChiCTR2100045034Phase 4Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of ruxolitinib in graft-versus-host disease (GVHD) (2 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoints: Safety and Cumulative incidence of grade II-IV acute GVHD at 100 days. Started May 2021; status: recruiting.
02
Drugs
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on ChiCTR2100045034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045034.